Chlorhexidine Monotherapy with Adjunctive Topical Corticosteroids for Acanthamoeba Keratitis

Purpose: To assess the efficacy of chlorhexidine monotherapy for Acanthamoeba keratitis, and to determine the therapeutic outcomes of concomitant topical corticosteroids. Methods: In this prospective interventional case series, 31 eyes of 31 patients with Acanthamoeba keratitis (AK) were treated with chlorhexidine 0.02% as monotherapy, from April 2010 to April 2011. The diagnosis of AK was made based on clinical manifestations and positive confocal microscopic (confoscan 3.4, Nidek Co. Ltd., Gamagori, Japan) results. We report the percentage of a favorable clinical response within two weeks of initiating treatment, worsening of the infection while receiving chlorhexidine, recovery of visual acuity (VA), duration of treatment with chlorhexidine and corticosteroids, necessity for addition of other anti-Acanthamoeba agents, presence of corneal scar at the end of the treatment, and need for penetrating keratoplasty (PK). Results: Two weeks after initiation of chlorhexidine, improvement in signs and symptoms was observed in 26 (83.9%) patients but 3 eyes required the addition of propamidine. After initial improvement in one patient, the infection worsened, necessitating the addition of Polyhexamethylene Biguanide (PHMB) and propamidine. A total of 26 (83.9%) patients received topical corticosteroids with mean duration of 65.8 ± 45.1 days. In 22 (71%) eyes, final visual acuity was ≥0.80. Improved VA occurred in 29 eyes (93.5%). Optical PK was considered in 3 (9.7%) eyes and a corneal scar developed in 8 (25.8%) eyes. Conclusion: Chlorhexidine is effective for monotherapy in AK and could be a good choice for initiating treatment. After the initial response to anti-Acanthamoeba agents, corticosteroids can be used as adjunctive therapy depending on the clinical condition.

[1]  Benjamin Clarke,et al.  Advances in the Diagnosis and Treatment of Acanthamoeba Keratitis , 2012, Journal of ophthalmology.

[2]  P. Nagra Clinical outcomes and prognostic factors associated with acanthamoeba keratitis , 2012 .

[3]  J. Whitcher,et al.  Practice Patterns and Opinions in the Treatment of Acanthamoeba Keratitis , 2011, Cornea.

[4]  S. Kilvington,et al.  Acanthamoeba keratitis: diagnosis and treatment update 2009. , 2009, American journal of ophthalmology.

[5]  J. Sugar,et al.  The Relative Value of Confocal Microscopy and Superficial Corneal Scrapings in the Diagnosis of Acanthamoeba Keratitis , 2008, Cornea.

[6]  C. Bunce,et al.  Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. , 2008, American journal of ophthalmology.

[7]  Sang Kyun Park,et al.  Acanthamoeba: keratopathogenicity of isolates from domestic tap water in Korea. , 2007, Experimental parasitology.

[8]  S. Yazdani,et al.  Sensitivity and Specificity of Confocal Scan in the Diagnosis of Infectious Keratitis , 2007, Cornea.

[9]  Jong Soo Lee,et al.  Cysticidal Effect on Acanthamoeba and Toxicity on Human Keratocytes by Polyhexamethylene Biguanide and Chlorhexidine , 2007, Cornea.

[10]  H. D. Cavanagh,et al.  Secondary Glaucoma Associated With Advanced Acanthamoeba Keratitis , 2006, Eye & contact lens.

[11]  W. Mathers Use of higher medication concentrations in the treatment of acanthamoeba keratitis. , 2006, Archives of ophthalmology.

[12]  Wei Chen,et al.  Acanthamoeba keratitis: clinical characteristics and management. , 2006, Ophthalmology.

[13]  G. Sutton,et al.  Six‐year review of Acanthamoeba keratitis in New South Wales, Australia: 1997–2002 , 2005, Clinical & experimental ophthalmology.

[14]  Takako Nakamura,et al.  A novel combination treatment of chlorhexidine gluconate, natamycin (pimaricin) and debridement for a Acanthamoeba keratitis. , 2003, Japanese journal of ophthalmology.

[15]  D. Seal,et al.  Acanthamoeba keratitis update—incidence, molecular epidemiology and new drugs for treatment , 2003, Eye.

[16]  D C Minassian,et al.  Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors , 2002, The British journal of ophthalmology.

[17]  Savitri Sharma,et al.  Patient characteristics, diagnosis, and treatment of non-contact lens related Acanthamoeba keratitis , 2000, The British journal of ophthalmology.

[18]  W. S. Head,et al.  Advances in the Management of Keratomycosis and Acanthamoeba Keratitis , 2000, Cornea.

[19]  T. Wygnanski-Jaffe,et al.  The Reculture Technique: Individualizing the Treatment of Acanthamoeba Keratitis , 2000, Cornea.

[20]  D. Fan,et al.  Polyhexamethylene biguanide (0.02%) alone is not adequate for treating chronic Acanthameoba keratitis , 2000, Eye.

[21]  G. Visvesvara,et al.  Treatment of acanthamoeba keratitis with chlorhexidine. , 1999, Ophthalmology.

[22]  S. Tuft,et al.  Outcome of acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. , 1997, Ophthalmology.

[23]  R. D. Stulting,et al.  The Role of Topical Corticosteroids in the Management of Acanthamoeba Keratitis , 1997, Cornea.

[24]  D. Seal,et al.  Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine , 1996, Eye.

[25]  L. Wilson,et al.  Effects of polyhexamethylene biguanide and chlorhexidine on four species of Acanthamoeba in vitro. , 1996, Current eye research.

[26]  J. D. Cameron,et al.  Confocal microscopy findings of Acanthamoeba keratitis. , 1996, American journal of ophthalmology.

[27]  T. Gray,et al.  Acanthamoeba keratitis: a sobering case and a promising new treatment. , 1994, Australian and New Zealand journal of ophthalmology.

[28]  D. Frazer,et al.  A review of 72 consecutive cases of Acanthamoeba keratitis, 1984–1992 , 1993, Eye.

[29]  J. H. Carr,et al.  Acanthamoeba keratitis in soft contact lens wearers. A case-control study. , 1987, JAMA.

[30]  Stinson Ek Acanthamoeba keratitis in soft-contact-lens wearers. , 1986, MMWR. Morbidity and mortality weekly report.

[31]  A. Steele,et al.  Amoebic infection of the eye. , 1974, Transactions of the ophthalmological societies of the United Kingdom.